Mylan Slumps in After-Hours Trading on Generic Advair Update
Down goes Mylan.

Pounded. 

Mylan NV (MYL) said Wednesday, June 13, that the U.S. Food and Drug Administration "has identified minor deficiencies" that the agency will relay in a letter later this month regarding Mylan's application for a generic version of  GlaxoSmithKline plc's (GSK) asthma drug Advair.

The FDA will issue a complete response letter, which indicates that an application is not yet ready for approval, on June 27.

Shares of Mylan fell 4.3% to $39.90 in after-hours trading. GlaxoSmithKline's American Depository Receipts were up 2.5% to $42.15.

"Because our Abbreviated New Drug Application has received a priority designation, our approval could be received prior to the standard 90-day time period following the date of our response to the Complete Response Letter," Mylan said.

More from Markets

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?

Online Retailers Hit by Supreme Court Ruling Requiring Sales Tax Collection

Online Retailers Hit by Supreme Court Ruling Requiring Sales Tax Collection

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech